Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
Medtronic has confirmed several instances of recharging sessions of a restoresensor implantable neurostimulator (ins) that ended without achieving a sufficient recharge to maintain stimulation therapy. this may cause the neurostimulator to enter into a rapid battery depletion state due to an error in the device causing the device battery level to decrease to the over discharged state within a couple days versus the 30 day decrease to the over discharged state in normal operation. when the neurostimulator battery is allowed to over discharge therapy is unavailable and the patient cannot charge the neurostimulator however battery function may be restored using the physician recharge mode of the recharger. as noted in the current labeling if three occurrences of over discharge occur the neurostimulator will no longer function and must be replaced.
“If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.